Seroatlas · Human Serome Atlas

TRIM7

E3 ubiquitin-protein ligase TRIM7

Also known as: GNIP, RNF90, TRIM7_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9C029
Gene: TRIM7
Ensembl: ENSG00000146054
Chromosome: 5
Canonical length: 511 aa
Protein class: Cancer-related genes, Enzymes, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Vesicles,Cytosol
Quaternary structure: Homodimer

OverviewNCBI Gene

The protein encoded by this gene is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1, a B-box type 2, and a coiled-coil region. The protein localizes to both the nucleus and the cytoplasm, and may represent a participant in the initiation of glycogen synthesis. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]

Canonical amino-acid sequenceUniProt

511 residues, UniProt reviewed canonical sequence.

>Q9C029|TRIM7
     1  MAAVGPRTGP GTGAEALALA AELQGEATCS ICLELFREPV SVECGHSFCR ACIGRCWERP
    61  GAGSVGAATR APPFPLPCPQ CREPARPSQL RPNRQLAAVA TLLRRFSLPA AAPGEHGSQA
   121  AAARAAAARC GQHGEPFKLY CQDDGRAICV VCDRAREHRE HAVLPLDEAV QEAKELLESR
   181  LRVLKKELED CEVFRSTEKK ESKELLKQMA AEQEKVGAEF QALRAFLVEQ EGRLLGRLEE
   241  LSREVAQKQN ENLAQLGVEI TQLSKLSSQI QETAQKPDLD FLQEFKSTLS RCSNVPGPKP
   301  TTVSSEMKNK VWNVSLKTFV LKGMLKKFKE DLRGELEKEE KVELTLDPDT ANPRLILSLD
   361  LKGVRLGERA QDLPNHPCRF DTNTRVLASC GFSSGRHHWE VEVGSKDGWA FGVARESVRR
   421  KGLTPFTPEE GVWALQLNGG QYWAVTSPER SPLSCGHLSR VRVALDLEVG AVSFYAVEDM
   481  RHLYTFRVNF QERVFPLFSV CSTGTYLRIW P

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRIM7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.38
Highest tissue expression: 181 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 181 nTPM
cerebellum: 52 nTPM
tongue: 48 nTPM
skin: 26 nTPM
esophagus: 25 nTPM
vagina: 8.7 nTPM

Single-cell type

myonuclei: 175 nCPM
esophageal apical cells: 158 nCPM
esophageal suprabasal cells: 155 nCPM
esophageal basal cells: 101 nCPM
suprabasal keratinocytes: 72 nCPM
respiratory basal cells: 53 nCPM

Immune cell

classical monocyte: 1.7 nTPM
T-reg: 0.9 nTPM
intermediate monocyte: 0.7 nTPM
MAIT T-cell: 0.7 nTPM
naive CD4 T-cell: 0.7 nTPM
naive CD8 T-cell: 0.5 nTPM

Brain region

cerebellum: 23 nTPM
medulla oblongata: 7.7 nTPM
cerebral cortex: 7 nTPM
midbrain: 7 nTPM
pons: 6.8 nTPM
thalamus: 5.3 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.64
gnomAD pLI: 0.03
gnomAD missense Z: 0.67
DepMap mean gene effect: 0.01
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TRIM7 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRIM7 as an antibody target. Whether an autoantibody or antibody against TRIM7 could matter depends on whether native TRIM7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRIM7 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TRIM7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...